Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 147 publications
Aquaporin-4's dynamic expression and biological variations within the tumor obscure the paraneoplastic phenomenon in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
Journal: Acta neuropathologica
Published: March 20, 2026
Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 25, 2025
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: December 11, 2024
MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 10, 2024
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Journal: The Lancet. Neurology
Published: November 10, 2023
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 07, 2023
Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
Journal: Annals of neurology
Published: April 23, 2023
Is Intravenous Immunoglobulin Effective in Reducing the Risk of Mortality and Morbidity in Neuroinvasive West Nile Virus Infection?: A Critically Appraised Topic.
Journal: The neurologist
Published: February 02, 2023
Cerebral enhancement in MOG antibody-associated disease.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 20, 2023
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.
Journal: Journal of managed care & specialty pharmacy
Published: November 25, 2022
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder.
Journal: Frontiers in neurology
Published: November 15, 2022
Last Updated: 09/26/2026